SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA ...

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

imageimageA major unresolved challenge to curing HIV-1 is its presence in the nucleus of infected cells. This study reports on new compounds that specifically block HIV-1 nuclear import by targeting ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A large, prospective study implicates high levels of interleukin 6 with severity of diabetic retinopathy and shows it may be ...

TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...

Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options ...

Protein-protein interactions (PPIs) are crucial for various cellular activities and disease development, and modulating PPIs using small molecule inhibitors (PPIIs) has gradually become a promising ...